The Association of Lipoprotein(a) and Neutrophil-to-Lymphocyte Ratio Combination with Atherosclerotic Cardiovascular Disease in Chinese Patients

References

• Li -J-J, Ma C-S, Zhao D, Yan X-W. Lipoprotein(a) and Cardiovascular Disease in Chinese Population: a Beijing Heart Society Expert Scientific Statement. JACC: Asia. 2022;2(6):653–665. doi:10.1016/j.jacasi.2022.08.015
   PubMedGoogle Scholar
• Erqou S, Kaptoge S, Perry PL, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA. 2009;302(4):412–423.
   PubMed Web of Science ®Google Scholar
• Kamstrup PR, Benn M, Tybjaerg-Hansen A, Nordestgaard BG. Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study. Circulation. 2008;117(2):176–184. doi:10.1161/CIRCULATIONAHA.107.715698
   PubMed Web of Science ®Google Scholar
• Ellis KL, Boffa MB, Sahebkar A, Koschinsky ML, Watts GF. The renaissance of lipoprotein(a): brave new world for preventive cardiology. Prog Lipid Res. 2017;68:57–82.
   PubMed Web of Science ®Google Scholar
• Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA. 2009;301(22):2331–2339.
   PubMed Web of Science ®Google Scholar
• Thanassoulis G, Campbell CY, Owens DS, et al. Genetic associations with valvular calcification and aortic stenosis. N Engl J Med. 2013;368(6):503–512.
   PubMed Web of Science ®Google Scholar
• Clarke R, Peden JF, Hopewell JC, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med. 2009;361(26):2518–2528.
   PubMed Web of Science ®Google Scholar
• Willeit P, Ridker PM, Nestel PJ, et al. Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials. Lancet. 2018;392(10155):1311–1320.
   PubMed Web of Science ®Google Scholar
• Tsimikas S, Hall JL. Lipoprotein(a) as a potential causal genetic risk factor of cardiovascular disease: a rationale for increased efforts to understand its pathophysiology and develop targeted therapies. J Am Coll Cardiol. 2012;60(8):716–721.
   PubMed Web of Science ®Google Scholar
• Liu HH, Cao YX, Jin JL, et al. Association of lipoprotein(a) levels with recurrent events in patients with coronary artery disease. Heart. 2020;106(16):1228–1235.
   PubMed Web of Science ®Google Scholar
• Kaiser Y, Daghem M, Tzolos E, et al. Association of Lipoprotein(a) With Atherosclerotic Plaque Progression. J Am Coll Cardiol. 2022;79(3):223–233.
   PubMed Web of Science ®Google Scholar
• Muramatsu Y, Minami Y, Kato A, et al. Lipoprotein (a) level is associated with plaque vulnerability in patients with coronary artery disease: an optical coherence tomography study. Int J Cardiol Heart Vasc. 2019;24:100382.
   PubMed Web of Science ®Google Scholar
• Tardif JC, Kouz S, Waters DD, et al. Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. N Engl J Med. 2019;381(26):2497–2505.
   PubMed Web of Science ®Google Scholar
• Araos P, Figueroa S, Amador CA. The role of neutrophils in hypertension. Int J Mol Sci. 2020;21(22):654.
   PubMed Web of Science ®Google Scholar
• Sesti-Costa R, de Moraes-Vieira P, Cervantes-Barragan L. Dendritic cells: immune response in infectious diseases and autoimmunity. Mediators Inflamm. 2020;2020:2948525.
   PubMed Web of Science ®Google Scholar
• Duffy BK, Gurm HS, Rajagopal V, Gupta R, Ellis SG, Bhatt DL. Usefulness of an elevated neutrophil to lymphocyte ratio in predicting long-term mortality after percutaneous coronary intervention. Am J Cardiol. 2006;97(7):993–996.
   PubMed Web of Science ®Google Scholar
• Uthamalingam S, Patvardhan EA, Subramanian S, et al. Utility of the neutrophil to lymphocyte ratio in predicting long-term outcomes in acute decompensated heart failure. Am J Cardiol. 2011;107(3):433–438.
   PubMed Web of Science ®Google Scholar
• Kalay N, Dogdu O, Koc F, et al. Hematologic parameters and angiographic progression of coronary atherosclerosis. Angiology. 2012;63(3):213–217.
   PubMed Web of Science ®Google Scholar
• Lee CD, Folsom AR, Nieto FJ, Chambless LE, Shahar E, Wolfe DA. White blood cell count and incidence of coronary heart disease and ischemic stroke and mortality from cardiovascular disease in African-American and White men and women: atherosclerosis risk in communities study. Am J Epidemiol. 2001;154(8):758–764.
   PubMed Web of Science ®Google Scholar
• Chalela JA. Evaluating the carotid plaque: going beyond stenosis. Cerebrovasc Dis. 2009;27(Suppl 1):19–24.
   PubMedGoogle Scholar
• Li X, Li J, Wu G. Relationship of Neutrophil-to-Lymphocyte Ratio with Carotid Plaque Vulnerability and Occurrence of Vulnerable Carotid Plaque in Patients with Acute Ischemic Stroke. Biomed Res Int. 2021;2021:6894623.
   PubMed Web of Science ®Google Scholar
• Cury RC, Abbara S, Achenbach S, et al. CAD-RADS(TM) Coronary Artery Disease - Reporting and Data System. An expert consensus document of the Society of Cardiovascular Computed Tomography (SCCT), the American College of Radiology (ACR) and the North American Society for Cardiovascular Imaging (NASCI). J Cardiovasc Comput Tomogr. 2016;10(4):269–281.
   PubMed Web of Science ®Google Scholar
• Chinese Association of Radiologists. Chinese Association of Radiologists. Chin J Radiol. 2022;56(6):595–607.
   Google Scholar
• Beijing Heart Association. Expert Statement on the Relationship Between Lipoprotein(a) and Cardiovascular Disease Risk and Clinical Management. Chin Circulation J. 2021;36(12):1158–1167.
   Google Scholar
• Peng S, Shen T, Liu J, et al. Uncontrolled Hypertension Increases with Age in an Older Community-Dwelling Chinese Population in Shanghai. Aging Dis. 2017;8(5):558–569.
   PubMed Web of Science ®Google Scholar
• Austen WG, Edwards JE, Frye RL, et al. A reporting system on patients evaluated for coronary artery disease. Report of the Ad Hoc Committee for Grading of Coronary Artery Disease, Council on Cardiovascular Surgery, American Heart Association. Circulation. 1975;51(4 Suppl):5–40.
   PubMedGoogle Scholar
• Goff DC, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25 Pt B):2935–2959.
   PubMed Web of Science ®Google Scholar
• Zhang W, Speiser JL, Ye F, et al. High-Sensitivity C-Reactive Protein Modifies the Cardiovascular Risk of Lipoprotein(a): multi-Ethnic Study of Atherosclerosis. J Am Coll Cardiol. 2021;78(11):1083–1094.
   PubMed Web of Science ®Google Scholar
• Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: executive Summary: a Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1046–e1081.
   PubMed Web of Science ®Google Scholar
• Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: a Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;140(11):e596–e646.
   PubMed Web of Science ®Google Scholar
• Hancock MA, Boffa MB, Marcovina SM, Nesheim ME, Koschinsky ML. Inhibition of plasminogen activation by lipoprotein(a): critical domains in apolipoprotein(a) and mechanism of inhibition on fibrin and degraded fibrin surfaces. J Biol Chem. 2003;278(26):23260–23269.
   PubMed Web of Science ®Google Scholar
• Romagnuolo R, Marcovina SM, Boffa MB, Koschinsky ML. Inhibition of plasminogen activation by apo(a): role of carboxyl-terminal lysines and identification of inhibitory domains in apo(a). J Lipid Res. 2014;55(4):625–634.
   PubMed Web of Science ®Google Scholar
• Undas A, Plicner D, Stepień E, Drwiła R, Sadowski J. Altered fibrin clot structure in patients with advanced coronary artery disease: a role of C-reactive protein, lipoprotein(a) and homocysteine. J Thromb Haemost. 2007;5(9):1988–1990.
   PubMed Web of Science ®Google Scholar
• Undas A, Slowik A, Wolkow P, Szczudlik A, Tracz W. Fibrin clot properties in acute ischemic stroke: relation to neurological deficit. Thromb Res. 2010;125(4):357–361.
   PubMed Web of Science ®Google Scholar
• Undas A, Cieśla-Dul M, Drążkiewicz T, Sadowski J. Altered fibrin clot properties are associated with residual vein obstruction: effects of lipoprotein(a) and apolipoprotein(a) isoform. Thromb Res. 2012;130(3):e184–7.
   PubMed Web of Science ®Google Scholar
• Skuza AA, Polak M, Undas A. Elevated lipoprotein(a) as a new risk factor of cerebral venous sinus thrombosis: association with fibrin clot properties. J Thromb Thrombolysis. 2019;47(1):8–15.
   PubMed Web of Science ®Google Scholar
• Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation. 2005;111(11):1448–1454.
   PubMed Web of Science ®Google Scholar
• Curran FM, Bhalraam U, Mohan M, et al. Neutrophil-to-lymphocyte ratio and outcomes in patients with new-onset or worsening heart failure with reduced and preserved ejection fraction. ESC Heart Fail. 2021;8(4):3168–3179.
   PubMed Web of Science ®Google Scholar
• Li S, Chen H, Zhou L, Cui H, Liang S, Li H. Neutrophil-to-lymphocyte ratio predicts coronary artery lesion severity and long-term cardiovascular mortality in patients with unstable angina pectoris. Acta Cardiol. 2022;77(8):708–715.
   PubMed Web of Science ®Google Scholar
• Silberman S, Fink D. Neutrophil to Lymphocyte Ratio and Risk of Atrial Fibrillation. Am J Cardiol. 2019;123(11):1889.
   PubMed Web of Science ®Google Scholar
• Wang R, Chen PJ, Chen WH. Diet and exercise improve neutrophil to lymphocyte ratio in overweight adolescents. Int J Sports Med. 2011;32(12):982–986.
   PubMed Web of Science ®Google Scholar
• Fairweather D. Sex differences in inflammation during atherosclerosis. Clin Med Insights Cardiol. 2014;8(Suppl 3):49–59.
   PubMedGoogle Scholar
• Tomaniak M, Katagiri Y, Modolo R, et al. Vulnerable plaques and patients: state-of-The-art. Eur Heart J. 2020;41(31):2997–3004.
   PubMed Web of Science ®Google Scholar
• Navaravong L, Steenson C, Sigurdsson G. Coronary plaque type and burden by computed tomography angiography without association to C-reactive protein. N Am J Med Sci. 2014;6(6):260–265.
   PubMedGoogle Scholar